Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Phase 1b save search
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Published: 2022-03-16 (Crawled : 11:00) - globenewswire.com
ADAG | $2.65 -2.63% 740
|
Manufacturing
|
| O: 24.95%
H: 0.0%
C: -20.13%
adg126 safebody fda clearance phase 1b trial fda clearance phase 1 therapy antibody phase 2b
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells
Published: 2022-03-08 (Crawled : 17:00) - biospace.com/
TCBP | $1.485 -6.01% -6.4% 110K
|
|
| O: 8.36%
H: 12.75%
C: -5.38%
myeloid leukemia pos phase 1b leukemia cel phase 1 positive t-cell acute myeloid leukemia phase 2b
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
Published: 2022-03-02 (Crawled : 08:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -8.79%
cyad-101 clinical hold phase 1b trial cel phase 1 phase 2b
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
pln-7480 health phase 1b trial therapeutics phase 1 positive phase 2b
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
Published: 2022-02-28 (Crawled : 08:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -10.87%
H: 0.7%
C: -6.97%
cyad-101 phase 1b trial cel phase 1 phase 2b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-23 (Crawled : 01:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.87%
H: 0.84%
C: -1.12%
cd73 trial phase 1 antibody phase 1b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -1.25%
H: 1.21%
C: 1.04%
cd73 trial phase 1 antibody phase 1b
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
ACIU | $2.33 -2.1% -2.15% 320K
|
Health Technology
|
| O: 2.07%
H: 3.61%
C: 1.58%
aci-35 alzheimer phase 1b trial phase 1 aci-35.030 vaccine alzheimer’s alzheimer's phase 2b
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
Published: 2022-01-31 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 0.0%
H: 13.69%
C: 11.2%
solid tumors phase 1b trial therapeutics phase 1 positive phase 2b
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA
Published: 2022-01-26 (Crawled : 14:00) - biospace.com/
VCNX | $4.9631 -2.76% 3.5K
|
Health Technology
|
| O: 21.57%
H: 3.23%
C: -10.48%
ema phase 1b response phase 1 keytruda report pons vaccine semaphorin pepinemab enroll phase 2b
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
Published: 2022-01-24 (Crawled : 22:00) - biospace.com/
ETNB | $8.59 -3.7% -3.84% 870K
|
Health Technology
|
| O: -2.79%
H: 2.67%
C: -1.44%
bio89 treatment expansion phase 1b trial 100 phase 1 report topline results positive results topline nash phase 2b
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting
Published: 2022-01-24 (Crawled : 15:00) - biospace.com/
PBLA | News | $0.42 -6.31% 64K
|
Professional, Scientific, and T...
|
| O: -0.95%
H: 7.64%
C: 5.41%
sbp-101 phase 1b trial asco phase 1 gemcitabine phase 2b
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-01-19 (Crawled : 14:00) - biospace.com/
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 2.19%
H: 2.99%
C: -5.58%
fmx114 treatment atopic dermatitis dermatitis phase 1b trial therapeutics phase 1 phase 2b
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles
Published: 2022-01-19 (Crawled : 13:30) - biospace.com/
IMMX | $2.15 -6.52% -6.98% 60K
|
|
| O: 0.0%
H: 5.34%
C: -2.58%
imx-110 treatment phase 1b trial 100 phase 1 positive phase 2b
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
Published: 2022-01-13 (Crawled : 11:00) - biospace.com/
ADAG | $2.65 -2.63% 740
|
Manufacturing
|
| O: 0.11%
H: 0.23%
C: -2.74%
adg106 phase 1b trial cel lung cancer phase 1 cancer phase 2b nivolumab
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
Published: 2022-01-05 (Crawled : 14:00) - biospace.com/
EWTX | $16.08 2.75% 2.67% 430K
|
Manufacturing
|
| O: 16.33%
H: 14.93%
C: 5.27%
edg-5506 muscular dystrophy phase 1b trial therapeutics phase 1 topline results positive topline phase 2b
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2021-12-27 (Crawled : 13:30) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -9.76%
treatment phase 1b trial phase 1 soft tissue phase 2b
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
MREO | $2.785 0.18% 0.18% 570K
|
Health Technology
|
| O: 0.61%
H: 0.6%
C: -3.01%
mph966 covid-19 respiratory phase 1b trial covid disease phase 1 positive results topline phase 2b alvelestat
Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
Published: 2021-12-16 (Crawled : 07:00) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 2.91%
H: 0.0%
C: -1.88%
phase 1b trial cel phase 1 phase 2b
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.